
StemSight
Finland · Biotech & life sciences · Seed

Pleryon Therapeutics
China · Biotech & life sciences · Series A
Compatibility /100
66/100
High potentialWhy talk
- Pleryon Therapeutics has raised about $18.6M — investor introductions are realistic.
- StemSight likely needs funding for the next round — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; StemSight works on Ophthalmic cell therapy (cornea), Pleryon Therapeutics on Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerative aesthetics).
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
17.5 / 35 pts
Pleryon Therapeutics can help StemSight.
- StemSight likely needs funding for the next round — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
Market bridge
2.5 / 10 pts
Distant markets.
- Pleryon Therapeutics is based in China (Asia): a landing pad on another continent, both ways.
Customer potential
0.0 / 5 pts
Neither side has a product on the market yet.
No supporting signal in the records.
Sector synergy
11.3 / 15 pts
Same sector: peers.
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; StemSight works on Ophthalmic cell therapy (cornea), Pleryon Therapeutics on Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerative aesthetics).
Stage complementarity
35.0 / 35 pts
Strong mentoring / investor-intro potential.
- Pleryon Therapeutics has raised about $18.6M — investor introductions are realistic.
- Pleryon Therapeutics (Series A) is one step ahead of StemSight (Seed) — the freshest playbook for StemSight's next round.
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Investment”: Needs ↔ offers 35, Market bridge 10, Customer potential 5, Sector synergy 15, Stage complementarity 35. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 57/100 — high from 50, medium from 36.